GSK Announces US FDA Approval of Benlysta (Belimumab) for Pediatric Patients With Active Lupus Nephritis
Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis LONDON–(BUSINESS WIRE)–GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving … [Read more…]
